View source for Vesicular monoamine transporter 1

{{Short description|Protein found in humans}}
{{cs1 config|name-list-style=vanc}}
{{Infobox_gene}}
'''Vesicular monoamine transporter 1''' ('''VMAT1'''), also known as '''chromaffin granule amine transporter''' ('''CGAT''') or '''solute carrier family 18 member 1''' ('''SLC18A1'''), is a [[protein]] that in humans is encoded by the ''SLC18A1'' [[gene]]. VMAT1 is an [[integral membrane protein]], which is embedded in [[synaptic vesicle]]s and serves to transfer [[monoamine]]s, such as [[norepinephrine]], [[epinephrine]], [[dopamine]], and [[serotonin]], between the [[cytosol]] and synaptic vesicles.<ref name="discovery">{{cite journal |vauthors=Eiden LE, Schäfer MK, Weihe E, Schütz B | title = The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine | journal = Pflügers Arch. | volume = 447 | issue = 5 | pages = 636–40 |date=February 2004 | pmid = 12827358 | doi = 10.1007/s00424-003-1100-5 | s2cid = 20764857 }}</ref> SLC18A1 is an [[isoform]] of the [[vesicular monoamine transporter]].

== Discovery ==
The idea that there must be specific [[transport protein]]s associated with the uptake of monoamines and [[acetylcholine]] into vesicles developed due to the discovery of specific inhibitors which interfered with monoamine [[neurotransmission]] and also depleted monoamines in [[neuroendocrine]] tissues.<ref name="discovery" />  VMAT1 and [[VMAT2]] were first identified in rats upon cloning [[cDNA]]s for proteins which gave non-amine accumulating recipient cells the ability to sequester monoamines.<ref name="rat clone">{{cite journal |vauthors=Erickson JD, Eiden LE, Hoffman BJ | title = Expression cloning of a reserpine-sensitive vesicular monoamine transporter | journal = Proc. Natl. Acad. Sci. U.S.A. | volume = 89 | issue = 22 | pages = 10993–7 |date=November 1992 | pmid = 1438304 | pmc = 50469 | doi = 10.1073/pnas.89.22.10993| bibcode = 1992PNAS...8910993E | doi-access = free }}</ref>  Subsequently, human VMATs were cloned using human cDNA libraries with the rat [[homolog]]s as probes, and heterologous-cell amine uptake assays were performed to verify transport properties.<ref name="human clone">{{cite journal |vauthors=Erickson JD, Eiden LE | title = Functional identification and molecular cloning of a human brain vesicle monoamine transporter | journal = J. Neurochem. | volume = 61 | issue = 6 | pages = 2314–7 |date=December 1993 | pmid = 8245983 | doi = 10.1111/j.1471-4159.1993.tb07476.x | s2cid = 7544757 | url = https://zenodo.org/record/1230649 }}</ref>

== Structure ==
<!-- Deleted image removed: [[File:Theoretical Structure of VMAT1.png|thumb|left|alt=Theoretical Structure of VMAT1|Proposed 10 and 12 TMD structures of VMAT1.]] -->

Across [[mammalian]] species, VMATs have been found to be structurally well conserved; VMAT1s have an overall [[sequence identity]] exceeding 80%. However, there exists only a 60% sequence identity between the human VMAT1 and VMAT2.<ref name="sequenceID">{{cite journal |vauthors=Eiden LE, Schäfer MK, Weihe E, Schütz B | title = The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine | journal = Pflügers Arch. | volume = 447 | issue = 5 | pages = 636–40 |date=February 2004 | pmid = 12827358 | doi = 10.1007/s00424-003-1100-5 | s2cid = 20764857 }}</ref>

VMAT1 is an acidic [[glycoprotein]] with an apparent weight of 40 [[kDa]].<ref name="structure-function">{{cite journal | author = Wimalasena K | title = Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry | journal = Med Res Rev | volume = 31 | issue = 4 | pages = 483–519 |date=July 2011 | pmid = 20135628 | pmc = 3019297 | doi = 10.1002/med.20187 }}</ref> Although the [[crystallographic structure]] has not yet been fully resolved, VMAT1 is known to have either twelve [[transmembrane domain]]s (TMDs), based on Kyte-Doolittle [[hydrophobicity scale]] analysis<ref name="human clone"/> or ten TMDs, based on MAXHOM alignment.  MAXHOM alignment was determined using the "profile-fed neural network systems from Heidelberg" (PHD) program.<ref name="discovery"/>  The main difference between these two models arises from the placement of TMDs II and IV in the vesicle lumen or the [[cytoplasm]].

== Localization ==

===Cell types===
VMATs are found in a variety of cell types throughout the body, however, VMAT1 is found exclusively in [[neuroendocrine cells]], in contrast to VMAT2, which is also found in the [[peripheral nervous system|PNS]] and [[central nervous system|CNS]].  Specifically, VMAT1 is found in [[chromaffin cell]]s, [[enterochromaffin cell]]s, and [[small intensely fluorescent cell]]s (SIFs).<ref name=local>{{cite journal |vauthors=Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E | title = Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter | journal = Proc. Natl. Acad. Sci. U.S.A. | volume = 93 | issue = 10 | pages = 5166–71 |date=May 1996 | pmid = 8643547 | pmc = 39426 | doi =  10.1073/pnas.93.10.5166| bibcode = 1996PNAS...93.5166E | doi-access = free }}</ref>   Chromaffin cells are responsible for releasing the [[catecholamines]] (norepinephrine and [[epinephrine]]) into [[systemic circulation]].  Enterochromaffin cells are responsible for storing serotonin in the gastrointestinal tract.  SIFs are [[interneurons]] associated with the [[sympathetic nervous system]] which are managed by dopamine.

=== Vesicles ===
VMAT1 is found in both [[large dense-core vesicles]] (LDCVs) as well as in small [[synaptic vesicles]] (SSVs). This was discovered via studying rat adrenal medulla cells (PC12 cells).<ref name="PC12">{{cite journal |vauthors=Liu Y, Schweitzer ES, Nirenberg MJ, Pickel VM, Evans CJ, Edwards RH | title = Preferential localization of a vesicular monoamine transporter to dense core vesicles in PC12 cells | journal = J. Cell Biol. | volume = 127 | issue = 5 | pages = 1419–33 |date=December 1994 | pmid = 7962100 | pmc = 2120259 | doi =  10.1083/jcb.127.5.1419}}</ref>  LDCVs are 70-200&nbsp;nm in size and exist throughout the [[neuron]] ([[soma (biology)|soma]], [[dendrites]], etc.).  SSVs are much smaller (usually about 40&nbsp;nm) and typically exist as clusters in the presynaptic cleft.

== Function ==

=== Active transport of monoamines ===

==== Driving force ====
[[Image:Scheme secundary active transport-en.svg|thumb|400px|An example of secondary active transport]]
The [[active transport]] of monoamines from the cytosol into storage vesicles operates against a large (>10<sup>5</sup>) concentration gradient.  [[Secondary active transport]] is the type of active transport used, meaning that VMAT1 is an [[antiporter]].  This transport is facilitated via [[proton gradient]] generated by the protein proton [[ATPase]].  The inward transport of the monoamine is coupled with the efflux of two protons per monoamine.<ref name="transport">{{cite journal | author = Parsons SM | title = Transport mechanisms in acetylcholine and monoamine storage | journal = The FASEB Journal | volume = 14 | issue = 15 | pages = 2423–2434 |date=December 2000 | pmid = 11099460 | doi = 10.1096/fj.00-0203rev | doi-access = free | s2cid = 693587 }}</ref>  The first proton is thought to cause a change in VMAT1's [[Protein conformation|conformation]], which pushes a high affinity amine [[binding site]], to which the monoamine attaches.  The second proton then causes a second change in the conformation which pulls the monoamine into the vesicle and greatly reduces the affinity of the binding site for amines. A series of tests suggest that [[Histamine|His]]419, located between TMDs X and XI, plays the key role in the first of these conformational changes, and that [[Aspartic acid|Asp]]431, located on TMD XI, does likewise during the second change.<ref name="structure-function"/>

==== Inhibition ====
Several [[reuptake| reuptake inhibitors]] of VMATs are known to exist, including [[reserpine]] (RES), [[tetrabenazine]] (TBZ), [[dihydrotetrabenazine]] (DTBZOH), and [[ketanserin]] (KET).  It is thought that RES exhibits [[competitive inhibition]], binding to the same site as the monoamine substrate, as studies have shown that it can be displaced via introduction of norepinephrine.  TBZ, DTBZOH, and KET are thought to exhibit [[non-competitive inhibition]], instead binding to [[allosteric regulation|allosteric sites]] and decreasing the activity of the VMAT rather than simply blocking its substrate binding site.<ref name="structure-function"/>  It has been found that these inhibitors are less effective at inhibiting VMAT1 than VMAT2, and the inhibitory effects of the tetrabenazines on VMAT1 is negligible.<ref name="local"/>

=== Clinical significance ===

==== Pancreatic cancer ====
The expression of VMAT1 in healthy endocrine cells was compared to VMAT1 expression in infants with [[hyperinsulinemic hypoglycemia]] and adults with pancreatic endocrine tumors.<ref name="pancreas">{{cite journal |vauthors=Anlauf M, Eissele R, Schäfer MK, Eiden LE, Arnold R, Pauser U, Klöppel G, Weihe E | title = Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors | journal = J. Histochem. Cytochem. | volume = 51 | issue = 8 | pages = 1027–40 |date=August 2003 | pmid = 12871984 | doi = 10.1177/002215540305100806| s2cid = 24334855 | url = http://intramural.nimh.nih.gov/lcmr/smn/pdf/12871984.pdf | doi-access = free }}</ref>  Through [[immunohistochemistry]] (IHC) and [[in situ hybridization]] (ISH), they found VMAT1 and VMAT2 were located in mutually exclusive cell types, and that in insulinomas VMAT2 activity disappeared, suggesting that if only VMAT1 activity is present in the endocrine system, this type of cancer is likely.

==== Digestive system ====
VMAT1 also has effects on the modulation of [[gastrin]] processing in [[G cells]].  These intestinal endocrine cells process amine precursors, and VMAT1 pulls them into vesicles for storage.  The activity of VMAT1 in these cells has a seemingly inhibitory effect on the processing of gastrin.  Essentially, this means that certain compounds in the gut can be taken into these G cells and either amplify or inhibit the function of VMAT1, which will impact gastrin processing (conversion from G34 to G17).<ref name="gastrin">{{cite journal |vauthors=Hussain I, Bate GW, Henry J, Djali P, Dimaline R, Dockray GJ, Varro A | title = Modulation of gastrin processing by vesicular monoamine transporter type 1 (VMAT1) in rat gastrin cells | journal = J. Physiol. | volume = 517 | issue = 2| pages = 495–505 |date=June 1999 | pmid = 10332097 | pmc = 2269351 | doi = 10.1111/j.1469-7793.1999.00495.x  }}</ref>

Additionally, VMAT1 is known to play a role in the uptake and secretion of serotonin in the gut.  Enterochromaffin cells in the intestines will secrete serotonin in response to the activation of certain [[mechanosensor]]s.<ref name="gut">{{cite journal |vauthors=Chin A, Svejda B, Gustafsson BI, Granlund AB, Sandvik AK, Timberlake A, Sumpio B, Pfragner R, Modlin IM, Kidd M | title = The role of mechanical forces and adenosine in the regulation of intestinal enterochromaffin cell serotonin secretion | journal = Am. J. Physiol. Gastrointest. Liver Physiol. | volume = 302 | issue = 3 | pages = G397–405 |date=February 2012 | pmid = 22038827 | doi = 10.1152/ajpgi.00087.2011 | pmc=3287403}}</ref>  The regulation of serotonin in the gut is critically important, as it modulates appetite and controls intestinal contraction.

==== Protection against hypothermia ====
Presence of VMAT1 in cells has been shown to protect them from the damaging effects of cooling and rewarming associated with [[hypothermia]].<ref name="hypo">{{cite journal |vauthors=Talaei F, Schmidt M, Henning RH | title = Induction of VMAT-1 and TPH-1 expression induces vesicular accumulation of serotonin and protects cells and tissue from cooling/rewarming injury | journal = PLOS ONE | volume = 7 | issue = 1 | pages = e30400 | year = 2012 | pmid = 22253933 | pmc = 3257274 | doi = 10.1371/journal.pone.0030400 | bibcode = 2012PLoSO...730400T | doi-access = free }}</ref> Experiments were carried out on [[Aorta|aortic]] and [[kidney]] cells and [[Tissue (biology)|tissues]].  Evidence was found that an accumulation of serotonin using VMAT1 and [[TPH1]] allowed for the subsequent release of serotonin when exposed to cold temperatures.  This allows [[cystathionine beta synthase]] (CBS) mediated generation of [[hydrogen disulfide|H<sub>2</sub>S]].  The protection against the damage caused by hypothermia is due to a reduction in the generation of [[reactive oxygen species]] (ROS), which can induce [[apoptosis]], due to the presence of H<sub>2</sub>S.<ref name="ROS">{{cite journal |vauthors=Talaei F, Bouma HR, Van der Graaf AC, Strijkstra AM, Schmidt M, Henning RH | title = Serotonin and dopamine protect from hypothermia/rewarming damage through the CBS/H2S pathway | journal = PLOS ONE | volume = 6 | issue = 7 | pages = e22568 | year = 2011 | pmid = 21829469 | pmc = 3144905 | doi = 10.1371/journal.pone.0022568 | bibcode = 2011PLoSO...622568T | doi-access = free }}</ref>

==== Mental disorders ====
VMAT1 (SLC18A1) maps to a shared [[bipolar disorder]](BPD)/[[schizophrenia]] [[locus (genetics)|locus]], which is located on [[chromosome 8]]p21.<ref name="bipolar">{{cite journal |vauthors=Lohoff F, Dahl J, Ferraro T, Arnold S, Gallinat J, Sander T, Berrettini W | title = Variations in the vesicular monoamine transporter type 1 gene (VMAT1/SLC18A1) are associated with bipolar I disorder | journal = Neuropsychopharmacology | volume = 31 | issue = 12 | pages = 2739–2747 |date=December 2006 | pmid =  16936705 | doi =  10.1038/sj.npp.1301196 | pmc=2507868}}</ref><ref>{{cite journal | vauthors = Lohoff FW, Weller AE, Bloch PJ, Buono RJ, Doyle GA, Ferraro TN, Berrettini WH | title = Association between polymorphisms in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) on chromosome 8p and schizophrenia | language = en | journal = Neuropsychobiology | volume = 57 | issue = 1–2 | pages = 55–60 | date = 2008 | pmid = 18451639 | doi = 10.1159/000129668 | s2cid = 39523023 }}</ref>  It is thought that disruption in transport of monoamine neurotransmitters due to variation in the VMAT1 gene may be relevant to the [[etiology]] of these mental disorders.  One study looked at a population of European descent, examining the genotypes of a bipolar group and a control group.  The study confirmed expression of VMAT1 in the brain at a protein and [[mRNA]] level, and found a significant difference between the two groups, suggesting that, at least for people of European descent, variation in the VMAT1 gene may confer susceptibility.<ref name="bipolar"/>  A second study examined a population of Japanese individuals, one group healthy and the other schizophrenic.  This study resulted in mostly inconclusive findings, but some indications that variation in the VMAT1 gene would confer susceptibility to schizophrenia in Japanese women.<ref name="schizophrenia">{{cite journal |vauthors=Richards M, Iijima Y, Kondo H, Shizuno T, Hori H, Arima K, Saitoh O, Kunugi H | title = Association study of the vesicular monoamine transporter 1 (VMAT1) gene with schizophrenia in a Japanese population | journal = Behav Brain Funct | volume = 2 | pages = 39 | year = 2006 | pmid = 17134514 | pmc = 1697819 | doi = 10.1186/1744-9081-2-39 | doi-access = free }}</ref>  While these studies provide some promising insight into the cause of some of the most prevalent mental disorders, it is clear that additional research will be necessary in order to gain a full understanding.

==References==
{{Reflist|35em}}

==External links==
* {{MeshName|Vesicular+Monoamine+Transporter+1}}

{{Neurotransmitter transporters}}
{{Membrane transport proteins}}
{{Adrenergics}}
{{Dopaminergics}}
{{Histaminergics}}
{{Serotonergics}}

[[Category:Amphetamine]]
[[Category:Biogenic amines]]
[[Category:Molecular neuroscience]]
[[Category:Neurotransmitter transporters]]
[[Category:Receptors]]
[[Category:Signal transduction]]
[[Category:Solute carrier family]]